Skip to content

Introducing Our New Showreel

We’re excited to unveil our latest showreel, a visual journey through the therapeutic areas and scientific stories that have shaped our recent work. In just two minutes, this reel captures recent years of collaboration, storytelling, and discovery in some of the most dynamic fields of medical science. From oncology and mRNA science to hematology, neurology, …

mRNAs as Medicines Animation

Moderna was creating a curriculum to inspire and educate learners about the opportunity mRNA presents as a medicine. The objective was to create an engaging online lecture that would serve both internal company training and public education. For XVIVO, it involved producing over 30 minutes of high-quality 3D animation focusing on mRNA technology, molecular and cellular processes, and therapeutic advancements.

Alpha-1 Antitrypsin Deficiency (AATD) Animation

XVIVO and Korro Bio continued their partnership to create an animation for Korro’s RNA editing oligonucleotide candidate for alpha-1 antitrypsin deficiency (AATD) from their proprietary OPERA™ platform.

SONNET PLATFORM MOA ANIMATION

Sonnet BioTherapeutics requested an animation to help explain how their Fully Human Albumin Binding (FHAB) platform functions and the potential benefits of the platform over existing anti-tumor therapies. With vivid colors and key lighting details, the FHAB is clearly the star of the show in this animation.

XOLREMDI WHIM Syndrome MOA Animation

X4 Pharmaceuticals wanted to create a 3D medical animation for the launch of their therapeutic XOLREMDI, indicated for the treatment of WHIM syndrome, a rare immunodeficiency disorder. The main goal was to communicate the complexity of WHIM syndrome and how XOLREMDI cuts through this complexity by targeting the underlying cause of the disease. 

SL-172154 MOA Animation

Shattuck Labs enlisted XVIVO to develop a mechanism of action animation for their ARC platform (or Agonist Redirected Checkpoint), which links checkpoint blockade and immune co-stimulation in a single molecule, to treat cancer.

KV7 MOA Animation

Biohaven Pharmaceuticals and XVIVO teamed up again, this time to create a mechanism of action animation for BHV-7000, their recently-acquired Kv7 activator. The BHV-7000 molecule blocks the action of the voltage-gated Kv7 potassium ion channel, which exquisitely regulates the excitability of neurons in the central nervous system.

Werewolf Therapeutics PREDATOR platform

XVIVO recently partnered with Werewolf Therapeutics to create an animation about their INDUKINE molecules and how the molecules could transform immunotherapy as it is practiced today. Werewolf leadership had worked with XVIVO on a previous animation and really enjoyed the process and the final product. So it was an easy decision to pick a scientific animation studio when Werewolf needed help visualizing their science.

Predator Platform Technology Animation

XVIVO recently partnered with Werewolf Therapeutics to create an animation about their INDUKINE molecules and how the molecules could transform immunotherapy as it is practiced today.